{
  "claim_id": "claim_001",
  "claim": "Flublok contains 3x the hemagglutinin (HA) antigen content of standard-dose flu vaccines, which has been linked to greater immunogenicity vs standard-dose flu vaccines.",
  "document": "Liu_et_al.__2024_",
  "verified_evidence": [
    {
      "id": 1,
      "quote": "a cell culture based influenza vaccine (Flucelvax Quadrivalent by Seqirus, Inc., ccIIV4) and a recombinant influenza vaccine (Flublok Quadrivalent by Sanofi Pasteur, RIV4). RIV4 contains 3 times the intended 45 \u00b5g HA/dose/strain compared to IIV4 and ccIIV4 (15 \u00b5g HA/dose/strain).",
      "supports_claim": true,
      "explanation": "The quote directly states that Flublok (RIV4) contains 3 times the hemagglutinin (HA) antigen content per strain compared to standard-dose flu vaccines (IIV4 and ccIIV4), which supports the first part of the claim. The document also discusses immunogenicity comparisons between these vaccines, with RIV4 (Flublok) showing higher antibody responses in some cases, supporting the link to greater immunogenicity. Therefore, the quote genuinely supports the claim as stated.",
      "presence_explanation": "A semantically equivalent version of the quote appears on page 2 of the document: 'a cell culture based influenza vaccine (Flucelvax Quadrivalent by Seqirus, Inc., ccIIV4) and a recombinant influenza vaccine (Flublok Quadrivalent by SanofiPasteur, RIV4). RIV4 contains 3 times the i d 45 HA/d / ...d'. The text is partially cut off, but the context and numbers match the quote: RIV4 (Flublok) contains 3 times the intended 45 \u00b5g HA/dose/strain compared to IIV4 and ccIIV4 (15 \u00b5g HA/dose/strain). The numbers and vaccine names are present and the meaning is preserved.",
      "support_explanation": "The quote directly states that Flublok (RIV4) contains 3 times the hemagglutinin (HA) antigen content per strain compared to standard-dose flu vaccines (IIV4 and ccIIV4), which supports the first part of the claim. The document also discusses immunogenicity comparisons between these vaccines, with RIV4 (Flublok) showing higher antibody responses in some cases, supporting the link to greater immunogenicity. Therefore, the quote genuinely supports the claim as stated.",
      "original_relevance": "This quote explicitly states that Flublok (RIV4) contains 3 times the hemagglutinin (HA) antigen content per strain compared to standard-dose flu vaccines (IIV4 and ccIIV4), directly supporting the first part of the claim."
    },
    {
      "id": 2,
      "quote": "In year 1, RIV4 induced higher neutralizing and total HA head binding antibodies to cell- A (H3N2) virus than ccIIV4 and IIV4.",
      "supports_claim": true,
      "explanation": "The quote directly supports the second part of the claim by stating that RIV4 (Flublok) induced higher neutralizing and total HA head binding antibodies (i.e., greater immunogenicity) to cell-based A (H3N2) virus compared to standard-dose vaccines (ccIIV4 and IIV4). The document also explicitly states elsewhere that 'RIV4 contains 3 times the...HA/d...' compared to IIV4 and ccIIV4, supporting the first part of the claim about antigen content. Thus, the quote, in the context of the document, genuinely supports the claim.",
      "presence_explanation": "The quote, 'In year 1, RIV4 induced higher neutralizing and total HA head binding antibodies to cell- A (H3N2) virus than ccIIV4 and IIV4,' appears in the document on the first page, with only minor formatting differences (e.g., 'A (H3 N2)' instead of 'A (H3N2)'). The factual content and meaning are preserved.",
      "support_explanation": "The quote directly supports the second part of the claim by stating that RIV4 (Flublok) induced higher neutralizing and total HA head binding antibodies (i.e., greater immunogenicity) to cell-based A (H3N2) virus compared to standard-dose vaccines (ccIIV4 and IIV4). The document also explicitly states elsewhere that 'RIV4 contains 3 times the...HA/d...' compared to IIV4 and ccIIV4, supporting the first part of the claim about antigen content. Thus, the quote, in the context of the document, genuinely supports the claim.",
      "original_relevance": "This quote provides direct evidence that RIV4 (Flublok), which contains 3x the HA antigen, resulted in greater immunogenicity (higher neutralizing and HA head binding antibodies) compared to standard-dose vaccines, supporting the second part of the claim."
    },
    {
      "id": "comp_1",
      "quote": "In this randomized trial (Clinical trials gov: NCT03722589), sera pre- and post vaccination with quadrivalent inactivated egg based (IIV4), cell culture based (ccIIV4), and recombinant (RIV4) influenza vaccines were compared. RIV4 contains 3 times the intended 45 \u00b5g HA/dose/strain compared to IIV4 and ccIIV4 (15 \u00b5g HA/dose/strain).",
      "supports_claim": true,
      "explanation": "The quote directly supports the first part of the claim by explicitly stating that RIV4 (Flublok) contains 3 times the hemagglutinin (HA) antigen content per strain compared to standard-dose flu vaccines (IIV4 and ccIIV4). The second part of the claim, regarding greater immunogenicity, is also supported elsewhere in the document (e.g., 'In year 1, RIV4 induced higher neutralizing and total HA head binding antibodies to cell- A (H3 N2) virus than ccIIV4 and IIV4'), but the quote itself is focused on the antigen content. Thus, the quote genuinely supports the claim as stated.",
      "presence_explanation": "The quote appears in the document on page 1: 'In this randomized trial (Clinical trials gov: NCT03722589), sera pre- and post vaccination with quadrivalent inactivated egg based (IIV4), cell culture based (ccIIV4), and recombinant (RIV4) influenza vaccines were compared. RIV4 contains 3 times the i d 45 HA/d / ...d' and on page 9: 'IIV4 and ccIIV4 (15 \u00b5g HA/dose/strain).' The quote as extracted is semantically equivalent to the document text, stating that RIV4 (Flublok) contains 3 times the intended 45 \u00b5g HA/dose/strain compared to IIV4 and ccIIV4 (15 \u00b5g HA/dose/strain).",
      "support_explanation": "The quote directly supports the first part of the claim by explicitly stating that RIV4 (Flublok) contains 3 times the hemagglutinin (HA) antigen content per strain compared to standard-dose flu vaccines (IIV4 and ccIIV4). The second part of the claim, regarding greater immunogenicity, is also supported elsewhere in the document (e.g., 'In year 1, RIV4 induced higher neutralizing and total HA head binding antibodies to cell- A (H3 N2) virus than ccIIV4 and IIV4'), but the quote itself is focused on the antigen content. Thus, the quote genuinely supports the claim as stated.",
      "original_relevance": "This quote explicitly states that Flublok (RIV4) contains three times the hemagglutinin (HA) antigen content per strain compared to standard-dose flu vaccines (IIV4 and ccIIV4), directly supporting the first part of the claim."
    }
  ],
  "verification_stats": {
    "total_verified": 3
  },
  "image_evidence": []
}